Thermo Fisher Scientific, Inc.

• Revenue: $24,358 million. 

EMD Serono, Inc.

• Revenue: $220.30 million. 

Coopersurgical, Inc.

• Revenue: $2,532.8 million.

Progyny, Inc.

• Revenue: $105.4 million. 

Irvine Scientific

• Revenue: $31.98 million.

Hamilton Thorne, Inc.

• Revenue: $29.21 million.

The Baker Company, Inc.

• Revenue: $28.15 million. 

Biogenics

• Revenue: $8.4 million.

ESCO Micro PTE

• Revenue: $6.64 million.

• Note that while this company is headquartered in Singapore, it has locations in the U.S. 

Boston IVF

• Revenue: $400,000 

Research Strategy

Thermo Fisher Scientific, Inc.

• Services offered by Thermo Fisher Scientific include cell culture media services, instrument services, molecular biology services, and real-time PCR custom services. These services are provided through their premier brands, namely, Invitrogen, Applied Biosystems, Fisher Scientific, Thermo Scientific, and Unity Lab Services.

• Marketing methods employed by the company include taking preemptive actions against emerging trends and industry changes, using close collaboration among teams in all the various businesses and regions, and incorporating its marketing channel activities such as the omnichannel program, email, and advertising within the company's core strategy.
• Its marketing methods also include the use of blogs, webinars, and social media platforms like Facebook, LinkedIn, YouTube, and Twitter.
• The company's revenue at the fiscal end year of 2018 stands at $24,358 million. By the third quarter of 2019, the company revenue still runs over $24 billion.
• In terms of market share, the company has a market value of $131,817.8 million and recorded sales growth of 16.45%.
• Strengths of the company include a wide range of product and service offerings across diverse industries and product support in terms of training & education, product documentation, and other technical information. Its reputation as a provider of quality products and services also works to its advantage in the market.
• Other strengths are customized and OEM applications, and eSolutions for eProcurement starting from "eCatalog to web-based PunchOut to full integration with eInvoicing." The company is also further strengthened by its increasing global presence after launching new bases in China and the US.
• Industry information suggests the company offers low risk in terms of investment opportunities, which is a strength. Another strength of the company is the volume of its assets, which stands at $56,232 million. 
• One major weakness of the company is on environmental matters. Its accrued liabilities on this issue were $69 million at the end of 2018. Also, because of the diversity of its products and services, it has to compete at all ends with various competitors, and this has reflected weakness in its market specialization. The lack of market specialization could be what reflected on its net income growth, which is comparatively low (32.04%) to that of its competitor (Coopersurgical, Inc.).

EMD Serono, Inc.

• Products and services of EMD Serono are in therapeutic areas such as neurology & immunology, endocrinology, fertility, and oncology. Medical information is also provided by health professionals, and oncology products are available as well.
• Marketing methods deployed by the company include leveraging on key channels such as federal, Medicaid, Medicare, commercial channels for the distribution of its products. It also targets influencers within the hospital, institutions, and traditional payers systems.
• Other marketing methods include close collaboration with significant local and international stakeholders by innovating contracting strategies and pricing recommendations. It also makes use of social media marketing with platforms such as YouTube, Facebook, Twitter, and LinkedIn.
• The company has an estimated revenue of €6,246 million ($6,881 million). This 2018 revenue is the addition of net sales for major products like oncology, neurology & immunology, fertility, general medicine & endocrinology, and other healthcare product lines.
• EMD Serono boasts of 9.2% market share in the fertility treatment market.
• The company's major strength lies in its research and development, having invested €2.2 billion ($2.42 billion) in 2018. Another strength of the company is its innovative solutions offering across lab technologies, therapeutics, connectivity, and services.
• One other strength of EMD Serono is its focus on supplier management in delivery reliability, high quality, and competitive prices. Industry information also suggests the company offers low risk in terms of investment opportunities, which is a strength.
• One notable weakness of the company is the annual increase in energy consumption from 2015 to 2018, which could raise environmental concern on its operations.

Coopersurgical, Inc.

• Products and services of CooperSurgical are "focused on advancing the health of women, babies, and families through a diversified portfolio of products and services including medical devices, fertility, genomics, diagnostics, and contraception." It also offers top-notch services, innovative technologies, and authentic products to its stakeholders globally.
• Marketing methods include the recruitment of senior director for each brand product. For instance, there were recruitments for Director of Marketing and Marketing Product Director for Paragard and surgical product line, respectively.
• Another marketing method employed is the strategic partnership with the media, advertising, and public relations agencies for the disciplined direction of its campaigns. The continuous training and development of its marketing team is one other method used by Coopersurgical.
• LinkedIn appears to be the only platform it uses for social media marketing. It has 13,502 followers.
• The company's revenue at the fiscal end year of October 2019 stands at $2,653.4 million.
• In terms of market share, the company has a market value of $16,369.5 million and recorded a sales growth of 4.76%.
• One significant strength of CooperSurgical is that it focuses on "selected segments of the family and women's health care market, supplying diagnostic products, services, and surgical instruments and accessories." Because of its selected segment, CooperSurgical can be the only choice for a complete procedure. Another strength of the company is that it is now a player in the IUD market after its acquisition of Paragard in 2018.
• Industry information suggests the company offers low risk in terms of investment opportunities, which is a strength. One other strength of the company is its astronomical net income growth, which stands at 233.6%. Both of these factors make it attractive for desirable investments.
• One weakness identified is that CooperSurgical may find it difficult to compete with entities with greater financial resources because of its limited diversity in the market. For instance, the company wants to make entry into "the larger hospital and outpatient surgical procedure segment of the market, but the market is presently dominated by bigger competitors such as Johnson & Johnson, Boston Scientific, Hologic, Olympus, and Medtronic." Also, the Paragard it acquired is already being sold by many manufacturers.

Research Strategy